

James Brett Case

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1115987/publications.pdf>

Version: 2024-02-01

45
papers

11,571
citations

134610

34
h-index

263392

45
g-index

69
all docs

69
docs citations

69
times ranked

17028
citing authors

#	ARTICLE	IF	CITATIONS
1	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. <i>Nature</i> , 2020, 583, 290-295.	13.7	1,695
2	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020, 584, 443-449.	13.7	956
3	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	15.2	838
4	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. <i>Nature</i> , 2021, 596, 109-113.	13.7	586
5	Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. <i>Nature Immunology</i> , 2020, 21, 1506-1516.	7.0	563
6	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020, 370, 950-957.	6.0	504
7	A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. <i>Cell</i> , 2020, 182, 744-753.e4.	13.5	486
8	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. <i>Nature</i> , 2022, 603, 687-692.	13.7	475
9	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. <i>Science</i> , 2020, 370, 426-431.	6.0	464
10	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. <i>Nature Medicine</i> , 2020, 26, 1422-1427.	15.2	450
11	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. <i>Cell</i> , 2020, 183, 169-184.e13.	13.5	446
12	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 28, 475-485.e5.	5.1	380
13	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , 2021, 184, 2183-2200.e22.	13.5	331
14	Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. <i>Cell</i> , 2021, 184, 1804-1820.e16.	13.5	297
15	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	5.9	237
16	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
17	Growth, detection, quantification, and inactivation of SARS-CoV-2. <i>Virology</i> , 2020, 548, 39-48.	1.1	209
18	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32105-32113.	3.3	192

#	ARTICLE	IF	CITATIONS
19	A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Journal of Immunology</i> , 2020, 205, 915-922.	0.4	186
20	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. <i>Cell Host and Microbe</i> , 2020, 28, 465-474.e4.	5.1	156
21	Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 20803-20813.	3.3	154
22	A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. <i>Cell Reports</i> , 2021, 36, 109400.	2.9	119
23	Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. <i>Clinical Chemistry</i> , 2020, 66, 1538-1547.	1.5	112
24	A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. <i>Cell Reports Medicine</i> , 2021, 2, 100230.	3.3	99
25	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. <i>Cell Reports</i> , 2021, 37, 110143.	2.9	94
26	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. <i>Nature Communications</i> , 2022, 13, .	5.8	93
27	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. <i>Immunity</i> , 2021, 54, 2399-2416.e6.	6.6	79
28	LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. <i>Nature</i> , 2020, 588, 308-314.	13.7	78
29	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	73
30	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. <i>Cell</i> , 2022, 185, 1572-1587.e11.	13.5	71
31	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. <i>Science Translational Medicine</i> , 2022, 14, eabn1252.	5.8	68
32	SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice. <i>Journal of Virology</i> , 2022, 96, JVI0151121.	1.5	58
33	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021, 54, 2159-2166.e6.	6.6	52
34	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. <i>Cell Host and Microbe</i> , 2022, 30, 53-68.e12.	5.1	52
35	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
36	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. <i>Cell Host and Microbe</i> , 2021, 29, 1151-1161.e5.	5.1	36

#	ARTICLE	IF	CITATIONS
37	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. <i>Journal of Molecular Biology</i> , 2021, 433, 167177.	2.0	31
38	The Translational Landscape of SARS-CoV-2-infected Cells Reveals Suppression of Innate Immune Genes. <i>MBio</i> , 2022, 13, .	1.8	21
39	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 2020, , 3606354.	0.4	16
40	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. <i>Cell Reports</i> , 2022, 38, 110561.	2.9	16
41	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. <i>Cell Reports</i> , 2021, 37, 109881.	2.9	14
42	JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis. <i>MBio</i> , 2022, 13, e0337721.	1.8	14
43	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
44	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. <i>MBio</i> , 2022, 13, e0323821.	1.8	11
45	Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies. <i>Cell Reports</i> , 2022, 39, 110905.	2.9	5